YD Bio Ltd(YDES) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:42 PM ET (Korea 10/30 05:42)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 80.12% | Shs Outstand | 70.8M | Perf Week | 38.44% |
| Market Cap | 0.42B | Forward P/E | - | EPS next Y | - | Insider Trans | 0.06% | Shs Float | 14.1M | Perf Month | -20.89% |
| Enterprise Value | 0.41B | PEG | - | EPS next Q | - | Inst Own | 0.4% | Short Float | 1.36% | Perf Quarter | 170.51% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | 43.14% | Short Ratio | 0.64 | Perf Half Y | 15.1% |
| Sales | - | P/B | 92.95 | EPS next 5Y | - | ROA | - | Short Interest | 0.19M | Perf YTD | -51.85% |
| Book/sh | 0.06 | P/C | 156.33 | EPS past 3/5Y | - 6.41% | ROE | - | 52W High | -63.31% ($16.00) | Perf Year | -55.66% |
| Cash/sh | 0.04 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 245.29% ($1.70) | Perf 3Y | -46.64% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 14.61% | Gross Margin | - | Volatility(W/M) | 22.23% 18.3% | Perf 5Y | -42.11% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.94 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.46 | EPS Q/Q | -116.03% | Profit Margin | - | RSI (14) | 51.81 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.23 | Sales Q/Q | - | SMA20 | -3.47% ($6.08) | Beta | -0.76 | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 15.09% ($5.1) | Rel Volume | 0.32 | Prev Close | $6.28 |
| Employees | 15 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 5.72% ($5.55) | Avg Volume(3M) | 0.30M | Price | $5.87 |
| IPO | 2020/12/23 | Option/Short | No/Yes | Trades | 1211 | Volume | 95,922 | Change | -6.53% |
🧬 Headquartered in Taipei, Taiwan, this biopharmaceutical company advances both blood-based early cancer diagnostics and stem cell/exosome-based therapeutics. Its business spans methylation-based oncology diagnostics, exosome-based ophthalmic treatments, and clinical trial supply services. The company pursues an integrated approach that connects diagnostics with therapeutics.
Over the past 1 year, roughly in the middle
63% below its 1-year high.
Traded less than usual. That is 32% of its average volume.
Holding long would have lost money
Bought 5 years ago, your return today would be -42.1%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
ONEQ Fidelity Nasdaq Composite Index ETF <0.01% It ranks #236 of 594 in the industry
Based on market cap of $416M.
FAQ
What kind of company is YDES?
YDES belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of YDES?
The market cap of YDES is approximately $416M, ranking 3,311 within its sector.
What is the 52-week high and low for YDES?
YDES has recorded a 52-week high of $16.00 and a low of $1.70.
